Sunshine Biopharma Announces Reverse Stock Split to Maintain NASDAQ Listing
The planned consolidation will reduce outstanding common shares from 15,219,383 to approximately 760,969.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Sunshine Biopharma (SBFM) announced a one-for-twenty reverse stock split effective at market open on October 26, 2026. Issued and outstanding common shares will fall from 15,219,383 to approximately 760,969. The company said the split is intended to regain compliance with Nasdaq's minimum bid price requirement for continued listing.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- None.
Negative
- Moderate point. Forward-looking: it has not happened yet and may not happen.One-for-twenty reverse split addresses Nasdaq minimum bid price noncompliance; effective October 26, 2026.
News Explained
For the announced one-for-twenty reverse split, the lower share count is paired with a proportionally higher per-share price; the split itself does not change company value.
Details
Market move: SBFM -18.66% vs previous close. 1-for-20 reverse split
On Oct 22, the day this news came out, the latest delayed price for SBFM is 18.66% below the previous close. Our momentum scanner has recorded 7 alerts for this stock so far that day. The latest delayed price is $0.18. Relative volume is exceptionally heavy at 8.4x the average.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
- Reverse split ratio
- 1-for-20
- Common stock; effective at market open on October 26, 2026
- Common shares outstanding
- 15,219,383 to approximately 760,969
- Reduction stated for the reverse stock split
- Effective date
- October 26, 2026
- At market open
Previous Stock split Reports
-
Prior reverse split aimed to regain Nasdaq minimum-bid compliance.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
reverse stock split financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
FORT LAUDERDALE, FL / ACCESS Newswire / October 22, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company specializing in generic and specialty prescription medications, including drugs in the areas of oncology and antivirals, today announced a one for twenty reverse split of its common stock, effective at market open on October 26, 2026. The reverse stock split was undertaken to regain compliance with Nasdaq's minimum bid price requirement for continued listing. The reverse stock split will reduce the Company's issued and outstanding shares of common stock from 15,219,383 to approximately 760,969.
About Sunshine Biopharma Inc.
Sunshine Biopharma currently has 60 generic prescription drugs on the market in Canada and approximately 12 additional drugs scheduled to be launched in the remainder of 2026. In addition, Sunshine Biopharma is conducting a proprietary drug development program which is comprised of (i) K1.1 mRNA, an mRNA-Lipid Nanoparticle targeted for liver cancer, and (ii) PLpro protease inhibitor, a small molecule for treatment of SARS Coronavirus infections. For more information, please visit: www.sunshinebiopharma.com.
Safe Harbor Forward-Looking Statements
This press release contains forward-looking statements which are based on current expectations, forecasts, and assumptions of Sunshine Biopharma Inc. (the "Company") that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected. These statements appear in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, including statements related to the Company's drug development activities, financial performance, and future growth. These risks and uncertainties are further described in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in the Company's filings with the SEC. Reference is hereby made to cautionary statements and risk factors set forth in the Company's most recent SEC filings.
For more information, please contact:
Camille Sebaaly, CFO
Direct Line: 514-814-0464
camille.sebaaly@sunshinebiopharma.com
SOURCE: Sunshine Biopharma Inc.
View the original press release on ACCESS Newswire
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.